Identification of the minimum region of Bordetella pertussis Vag8 required for interaction with C1 inhibitor.


Journal

Microbiology and immunology
ISSN: 1348-0421
Titre abrégé: Microbiol Immunol
Pays: Australia
ID NLM: 7703966

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 17 03 2020
revised: 06 05 2020
accepted: 10 05 2020
pubmed: 13 5 2020
medline: 16 4 2021
entrez: 13 5 2020
Statut: ppublish

Résumé

An autotransporter of Bordetella pertussis, virulence-associated gene 8 (Vag8), binds and inactivates the complement regulator, C1 inhibitor (C1-Inh), and plays a role in evasion of the complement system. However, the molecular interaction between Vag8 and C1-Inh remains unclear. Here, we localized the minimum region of Vag8 required for interaction with C1-Inh by examining the differently truncated Vag8 derivatives for the ability to bind and inactivate C1-Inh. The truncated Vag8 containing amino-acid residues 102-548, but not 102-479 and 202-648, showed the full activity of intact Vag8, suggesting that the separate 102-202 and 548-648 amino-acid regions of Vag8 mediate the interaction with C1-Inh.

Identifiants

pubmed: 32396237
doi: 10.1111/1348-0421.12799
pmc: PMC7497153
doi:

Substances chimiques

Bacterial Proteins 0
Complement C1 Inhibitor Protein 0
SERPING1 protein, human 0
Type V Secretion Systems 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

570-573

Subventions

Organisme : Japan Society for the Promotion of Science
ID : 17H04075
Organisme : Japan Society for the Promotion of Science
ID : 19K16638

Informations de copyright

© 2020 The Authors. Microbiology and Immunology published by The Societies and John Wiley & Sons Australia, Ltd.

Références

Mol Immunol. 2008 Oct;45(16):4057-63
pubmed: 18674818
Microbiol Immunol. 2020 Aug;64(8):570-573
pubmed: 32396237
J Infect Dis. 2007 Feb 15;195(4):585-8
pubmed: 17230419
Trends Microbiol. 2014 Feb;22(2):49-52
pubmed: 24485284
J Biol Chem. 2007 Jul 20;282(29):21100-9
pubmed: 17488724
PLoS Pathog. 2017 Jul 24;13(7):e1006531
pubmed: 28742139
Front Immunol. 2018 Jun 04;9:1172
pubmed: 29915576
Pediatr Infect Dis J. 2015 Sep;34(9):e222-32
pubmed: 26376316
Br J Pharmacol. 2011 Apr;162(7):1639-49
pubmed: 21175583
PLoS One. 2011;6(6):e20585
pubmed: 21695123
PLoS One. 2014 Aug 18;9(8):e105011
pubmed: 25133400
Microbiol Immunol. 2017 Sep;61(9):371-379
pubmed: 28752940

Auteurs

Naoki Onoda (N)

Department of Molecular Bacteriology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.

Yukihiro Hiramatsu (Y)

Department of Molecular Bacteriology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.

Shihono Teruya (S)

Department of Molecular Bacteriology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.

Koichiro Suzuki (K)

Department of Molecular Bacteriology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
The Research Foundation for Microbial Diseases of Osaka University (BIKEN), Suita, Osaka, Japan.

Yasuhiko Horiguchi (Y)

Department of Molecular Bacteriology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH